Journal of Diabetes and Its Complications
Volume 17, Issue 2 , Pages 98-104 , March 2003

Treatment of onychomycosis in the diabetic patient population

Received 19 February 2002 ,Revised 22 June 2002 ,Accepted 26 June 2002.

References 

  1. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. Journal of the American Podiatric Medical Association. 1999;89:339–345
  2. Anon. (2000). Ciclopirox (Penlac) nail lacquer for onychomycosis. Medical Letters on Drugs and Therapeutics, 42, 51–52.
  3. Boyko, W. L., Doyle, J. J., Ryu, S., & Gause, D. (1999, May). Onychomycosis and its impact on secondary infection development in the diabetic population [Abstract]. Presented at the 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA.
  4. Breckenridge A. Clinical significance of interactions with antifungal agents. British Journal of Dermatology. 1992;126(Suppl. 39):19–22
  5. Carstens J, Wendelboe P, Søgaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermato-Venereologica. 1994;74:391–392
  6. Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, Luc J, Vandermander J, Michel G. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacology. 1991;4:89–94
  7. Chien R-N, Yang L-J, Lin P-Y, Liaw Y-F. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 1997;25:103–107
  8. Del Rosso JQ. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Journal of the American Osteopathic Association. 1997;97:339–346
  9. Doyle, J. J., Boyko, W., Ryu, S., & Gause, D. (2000). Onychomycosis among diabetic patients: prevalence and impact of nonfungal foot infections [Abstract]. Presented at the 60th Scientific Sessions of the American Diabetes Association, San Antonio, TX, June 11, 2000.
  10. Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. Journal of the American Academy of Dermatology. 1998;38:S87–S94
  11. Drake LA, Patrick DL, Fleckman P, André J, Baran R, Haneke E, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. Journal of the American Academy of Dermatology. 1999;41:189–196
  12. Elewski BE. Diagnostic techniques for confirming onychomycosis. Journal of the American Academy of Dermatology. 1996;35(3 Pt 2):S6–S9
  13. Elewski BE. The effect of toenail onychomycosis on patient quality of life. International Journal of Dermatology. 1997;36:754–756
  14. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clinical Microbiology Reviews. 1998;11:415–429
  15. Elewski BE, Scher RK, Aly R, et al.  Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis. 1997;59:217–220
  16. Evans SL, Nixon BP, Lee I, Yee D, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. Journal of the American Geriatrics Society. 1991;39:241–245
  17. FDA Public Health Advisory. (2002). Food and Drug Administration Website. Available at: http://www.fda.gov/cder/drug/advisory/sporanox-lamisil/advisory.htm. Accessed January 18, 2002.
  18. Gupta AK. Ciclopirox nail lacquer topical solution 8%. Skin Therapy Letter. 2000;6:1–5
  19. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. Journal of the American Academy of Dermatology. 2000;43(Suppl. 4):S96–S102
  20. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs. 1998;55:645–674
  21. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology. 2000;43:S70–S80
  22. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. European Journal of Dermatology. 2000;10:379–384
  23. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. Journal of the American Podiatric Medical Association. 2000;90:495–501
  24. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicenter survey. British Journal of Dermatology. 1998;139:665–671
  25. Gupta AK, Malkin KF. Ciclopirox nail lacquer and podiatric practice. Journal of the American Podiatric Medical Association. 2000;90:502–507
  26. Haneke E, Abeck D, Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses. 1998;41:521–527
  27. Havu V, Brandt H, Heikkilä H, Hollmen A, Oksman R, Rantanen T, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. British Journal of Dermatology. 1997;136:230–234
  28. Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology. 1995;131:919–922
  29. Karchmer AW, Gibbons GW. Foot infections in diabetes: evaluation and management. Current Clinical Topics in Infectious Diseases. 1994;14:1–22
  30. Katz HI. Drug interactions of the newer oral antifungal agents. British Journal of Dermatology. 1999;141(Suppl. 56):26–32
  31. Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatologic Clinics. 1997;15:535–544
  32. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. Journal of Dermatology. 1993;3:115–117
  33. Lawry MA, Haneke E, Strobeck K, Matrin S, Zimmer B, Romano P. Methods for diagnosing onychomycosis. A comparative study and review of the literature. Archives of Dermatology. 2000;136:1112–1116
  34. Levy LA. Epidemiology of onychomycosis in special-risk populations. Journal of the American Podiatric Medical Association. 1997;87:546–550
  35. Lo ACY, Lui S-L, Lo W-K, Chan DTM, Cheng IKP. The interaction of terbinafine and cyclosporine A in renal transplant patients. British Journal of Clinical Pharmacology. 1996;43:340–341
  36. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Quality of Life Research. 1993;2:341–348
  37. Lugo-Somolinos A, Sánchez JL. Prevalence of dermatophytosis in patients with diabetes. Journal of the American Academy of Dermatology. 1992;26:408–410
  38. May 2001 safety-related drug labeling changes. (2002). Available at: http://www.fda.gov/medwatch/SAFETY/2001/May01.htm#sporan. Accessed January 18, 2002.
  39. O'Sullivan DP. Terbinafine: tolerability in general medical practice. British Journal of Dermatology. 1999;141(Suppl. 56):21–25
  40. Penk A, Pittrow L. Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. Mycoses. 1999;42(Suppl. 2):97–100
  41. Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. Journal of the American Academy of Dermatology. 1994;30:519–531
  42. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals. Prevention and management. Drug Safety. 1992;7:323–363
  43. Pollack R, Billstein SA. Safety of oral terbinafine for toenail onychomycosis. Journal of the American Podiatric Medical Association. 1997;87:565–570
  44. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics. 1999;16:285–295
  45. Rich P. Special patient populations: onychomycosis in the diabetic patient. Journal of the American Academy of Dermatology. 1996;35:S10–S12Suppl.
  46. Rich P. Onychomycosis and tinea pedis in patients with diabetes. Journal of the American Academy of Dermatology. 2000;43(Suppl. 5):S130–S134
  47. Rich P, Hare A. Onychomycosis in a special patient population: focus on the diabetic. International Journal of Dermatology. 1999;38(Suppl. 2):17–19
  48. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology. 1998;38:S77–S86
  49. Seebacher C, Nietsch K-H, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer 8% solution for the treatment of onychomycosis in diabetic patients. Cutis. 2001;68:17–22
  50. Tom CM, Kane MP. Management of toenail onychomycosis. American Journal of Health System Pharmacy. 1999;56:865–871
  51. Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology. 1996;34:595–600
  52. Verspeelt J, Marynissen G, Gupta AK, De Doncker P. Safety of itraconazole in diabetic patients. Dermatology. 1999;198:382–384

☆ This manuscript was supported by an unrestricted educational grant from Dermik Laboratories.

PII: S1056-8727(02)00199-X

Journal of Diabetes and Its Complications
Volume 17, Issue 2 , Pages 98-104 , March 2003

Article Tools

* Image Usage & Resolution